NO311218B1 - Nye disubstituerte trans-3,4,4a,5,6,10b-heksahydro-2H- naft[1,2-b]-1,4-oksaziner, en fremgangsmåte ved deres fremstillingog farmasöytiske sammensetninger inneholder disse - Google Patents
Nye disubstituerte trans-3,4,4a,5,6,10b-heksahydro-2H- naft[1,2-b]-1,4-oksaziner, en fremgangsmåte ved deres fremstillingog farmasöytiske sammensetninger inneholder disse Download PDFInfo
- Publication number
- NO311218B1 NO311218B1 NO19984007A NO984007A NO311218B1 NO 311218 B1 NO311218 B1 NO 311218B1 NO 19984007 A NO19984007 A NO 19984007A NO 984007 A NO984007 A NO 984007A NO 311218 B1 NO311218 B1 NO 311218B1
- Authority
- NO
- Norway
- Prior art keywords
- ppm
- compound
- trans
- formula
- hexahydro
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 5
- 230000008569 process Effects 0.000 title claims description 3
- AEMKDBZKQORZOA-VXGBXAGGSA-N (4ar,10br)-3,4,4a,5,6,10b-hexahydro-2h-benzo[h][1,4]benzoxazine Chemical class C1=CC=C2[C@H]3OCCN[C@@H]3CCC2=C1 AEMKDBZKQORZOA-VXGBXAGGSA-N 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 230000003287 optical effect Effects 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 47
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- -1 Cj-Cg-alkyl Chemical group 0.000 claims description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 238000007341 Heck reaction Methods 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 229940125890 compound Ia Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 241000700159 Rattus Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 230000003291 dopaminomimetic effect Effects 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 229940052760 dopamine agonists Drugs 0.000 description 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101150049660 DRD2 gene Proteins 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 238000012048 forced swim test Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 108010024941 iodothyronine deiodinase type II Proteins 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- UDEAASQJJIGOTN-IAGOWNOFSA-N (4ar,10br)-n,n-dimethyl-4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazine-9-carboxamide Chemical compound C1=C(C(=O)N(C)C)C=C2[C@H]3OCCN(CCC)[C@@H]3CCC2=C1 UDEAASQJJIGOTN-IAGOWNOFSA-N 0.000 description 1
- HBXAUVWJLFTKDA-FGZHOGPDSA-N (4ar,10br)-n-(4-methoxyphenyl)-4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazine-9-carboxamide Chemical compound C([C@@H]1[C@@H](C2=C3)OCCN1CCC)CC2=CC=C3C(=O)NC1=CC=C(OC)C=C1 HBXAUVWJLFTKDA-FGZHOGPDSA-N 0.000 description 1
- PAZHMMYMPVTXLZ-RTBURBONSA-N (4ar,10br)-n-butyl-4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazine-9-carboxamide Chemical compound C12=CC(C(=O)NCCCC)=CC=C2CC[C@@H]2[C@@H]1OCCN2CCC PAZHMMYMPVTXLZ-RTBURBONSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- QGRZOKIURVWFKN-IAGOWNOFSA-N 1-[(4ar,10br)-4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazin-9-yl]ethanone Chemical compound C1=C(C(C)=O)C=C2[C@H]3OCCN(CCC)[C@@H]3CCC2=C1 QGRZOKIURVWFKN-IAGOWNOFSA-N 0.000 description 1
- WAOQONBSWFLFPE-VIFPVBQESA-N 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC WAOQONBSWFLFPE-VIFPVBQESA-N 0.000 description 1
- GJLQYNALOOKSLR-UHFFFAOYSA-N 6-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound OC1=CC=C2CC(N(CCC)CCC)CCC2=C1 GJLQYNALOOKSLR-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- LTCHBBLDVKSDKC-HUUCEWRRSA-N [(4aR,10bR)-4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazin-9-yl] trifluoromethanesulfonate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)C=C2[C@H]3OCCN(CCC)[C@@H]3CCC2=C1 LTCHBBLDVKSDKC-HUUCEWRRSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000004002 dopaminergic cell Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- DTNBLXRAVILHMO-IAGOWNOFSA-N ethyl (4ar,10br)-4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazine-9-carboxylate Chemical compound C1=C(C(=O)OCC)C=C2[C@H]3OCCN(CCC)[C@@H]3CCC2=C1 DTNBLXRAVILHMO-IAGOWNOFSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229950001518 raclopride Drugs 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9710852A FR2767825A1 (fr) | 1997-09-01 | 1997-09-01 | Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO984007D0 NO984007D0 (no) | 1998-08-31 |
| NO984007L NO984007L (no) | 1999-03-02 |
| NO311218B1 true NO311218B1 (no) | 2001-10-29 |
Family
ID=9510643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19984007A NO311218B1 (no) | 1997-09-01 | 1998-08-31 | Nye disubstituerte trans-3,4,4a,5,6,10b-heksahydro-2H- naft[1,2-b]-1,4-oksaziner, en fremgangsmåte ved deres fremstillingog farmasöytiske sammensetninger inneholder disse |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6025356A (zh) |
| EP (1) | EP0899267B1 (zh) |
| JP (1) | JP4417451B2 (zh) |
| CN (1) | CN1088064C (zh) |
| AT (1) | ATE229513T1 (zh) |
| AU (1) | AU740928C (zh) |
| BR (1) | BR9803933A (zh) |
| CA (1) | CA2246482C (zh) |
| DE (1) | DE69810034T2 (zh) |
| DK (1) | DK0899267T3 (zh) |
| ES (1) | ES2189108T3 (zh) |
| FR (1) | FR2767825A1 (zh) |
| HK (1) | HK1020340A1 (zh) |
| HU (1) | HU226059B1 (zh) |
| NO (1) | NO311218B1 (zh) |
| NZ (1) | NZ331637A (zh) |
| PL (1) | PL194533B1 (zh) |
| PT (1) | PT899267E (zh) |
| ZA (1) | ZA987963B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| CA2496452A1 (en) * | 2002-08-30 | 2004-03-11 | Biostratum, Inc. | Inhibitors of post-amadori advanced glycation end products |
| MXPA05011225A (es) * | 2003-04-18 | 2005-12-14 | Pharmacia & Upjohn Co Llc | Politerapias. |
| FR2906249B1 (fr) | 2006-09-26 | 2008-12-19 | Servier Lab | Composes tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2098511A1 (en) | 2008-03-07 | 2009-09-09 | Solvias AG | Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring |
| CN102131790A (zh) * | 2008-06-27 | 2011-07-20 | H.隆德贝克有限公司 | 新型苯酚型和儿茶酚型胺及其前药 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1204745A (en) * | 1981-11-20 | 1986-05-20 | Merck Co. | Hexahydronaphth (1,2-b) -1,4 -oxazines |
| US4420480A (en) * | 1981-11-20 | 1983-12-13 | Merck & Co., Inc. | Hexahydronaphth[1,2-b]-1,4-oxazines |
| US4540691A (en) * | 1984-04-13 | 1985-09-10 | Nelson Research & Development Co. | Dopamine agonists and use thereof |
| US5486611A (en) * | 1989-07-13 | 1996-01-23 | The Upjohn Company | Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives |
| JPH05508408A (ja) * | 1990-06-15 | 1993-11-25 | ホイツトビー・リサーチ・インコーポレーテツド | ドーパミン作動性薬剤として有用な置換ナフトキサジン類 |
-
1997
- 1997-09-01 FR FR9710852A patent/FR2767825A1/fr active Pending
-
1998
- 1998-08-31 BR BR9803933-4A patent/BR9803933A/pt not_active Application Discontinuation
- 1998-08-31 NO NO19984007A patent/NO311218B1/no not_active IP Right Cessation
- 1998-08-31 HU HU9801951A patent/HU226059B1/hu not_active IP Right Cessation
- 1998-08-31 CN CN98119987A patent/CN1088064C/zh not_active Expired - Fee Related
- 1998-08-31 NZ NZ331637A patent/NZ331637A/xx not_active IP Right Cessation
- 1998-08-31 PL PL328285A patent/PL194533B1/pl not_active IP Right Cessation
- 1998-08-31 CA CA002246482A patent/CA2246482C/fr not_active Expired - Fee Related
- 1998-08-31 US US09/144,025 patent/US6025356A/en not_active Expired - Lifetime
- 1998-09-01 EP EP98402155A patent/EP0899267B1/fr not_active Expired - Lifetime
- 1998-09-01 DE DE69810034T patent/DE69810034T2/de not_active Expired - Lifetime
- 1998-09-01 DK DK98402155T patent/DK0899267T3/da active
- 1998-09-01 JP JP24691098A patent/JP4417451B2/ja not_active Expired - Fee Related
- 1998-09-01 AT AT98402155T patent/ATE229513T1/de active
- 1998-09-01 PT PT98402155T patent/PT899267E/pt unknown
- 1998-09-01 ES ES98402155T patent/ES2189108T3/es not_active Expired - Lifetime
- 1998-09-01 ZA ZA987963A patent/ZA987963B/xx unknown
- 1998-09-01 AU AU83024/98A patent/AU740928C/en not_active Ceased
-
1999
- 1999-11-25 HK HK99105446A patent/HK1020340A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK0899267T3 (da) | 2003-03-10 |
| EP0899267B1 (fr) | 2002-12-11 |
| CA2246482A1 (fr) | 1999-03-01 |
| HUP9801951A2 (hu) | 2000-02-28 |
| HU9801951D0 (en) | 1998-11-30 |
| HUP9801951A3 (en) | 2000-04-28 |
| AU8302498A (en) | 1999-03-11 |
| EP0899267A1 (fr) | 1999-03-03 |
| BR9803933A (pt) | 2001-04-24 |
| PT899267E (pt) | 2003-04-30 |
| PL194533B1 (pl) | 2007-06-29 |
| US6025356A (en) | 2000-02-15 |
| CN1088064C (zh) | 2002-07-24 |
| HU226059B1 (en) | 2008-04-28 |
| NO984007L (no) | 1999-03-02 |
| JPH11130759A (ja) | 1999-05-18 |
| ATE229513T1 (de) | 2002-12-15 |
| DE69810034T2 (de) | 2003-08-14 |
| FR2767825A1 (fr) | 1999-02-26 |
| DE69810034D1 (de) | 2003-01-23 |
| PL328285A1 (en) | 1999-03-15 |
| CN1222516A (zh) | 1999-07-14 |
| AU740928C (en) | 2002-05-16 |
| HK1020340A1 (en) | 2000-04-14 |
| NZ331637A (en) | 1999-07-29 |
| ZA987963B (en) | 1999-03-04 |
| ES2189108T3 (es) | 2003-07-01 |
| AU740928B2 (en) | 2001-11-15 |
| JP4417451B2 (ja) | 2010-02-17 |
| CA2246482C (fr) | 2002-11-26 |
| NO984007D0 (no) | 1998-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2756742B2 (ja) | Ｎ−アシル−２，３−ベンゾジアゼピン誘導体、その製造法、それを含有する医薬組成物、およびその製造法 | |
| JP2002535322A (ja) | ピペリジン、テトラヒドロピリジン及びピペラジン誘導体、それらの製造方法及びそれらの使用方法 | |
| HUT61719A (en) | Process for producing 2-aminotetraline derivatives and pharmaceutical compositions comprising such compounds | |
| MXPA05001882A (es) | Compuestos de imidazopiridina como agonistas del receptor 5-ht4. | |
| US20040266814A1 (en) | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | |
| PT2042480E (pt) | Derivado de aminoindano ou um seu sal | |
| JP2018509396A (ja) | ５−ｈｔ４受容体アゴニストとしてのアミド化合物 | |
| CA2688405A1 (en) | Therapeutic pyrazoloquinoline urea derivatives | |
| NO311218B1 (no) | Nye disubstituerte trans-3,4,4a,5,6,10b-heksahydro-2H- naft[1,2-b]-1,4-oksaziner, en fremgangsmåte ved deres fremstillingog farmasöytiske sammensetninger inneholder disse | |
| CA2274202A1 (en) | Diaza-spiro[3,5]nonane derivatives | |
| EA022776B1 (ru) | Арилсульфонамиды для лечения заболеваний цнс | |
| KR101463190B1 (ko) | ５ｈｔ６ 수용체 리간드인 술폰 화합물 | |
| NO316693B1 (no) | Nye indanolforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| JP3727569B2 (ja) | テトラヒドロキナゾリン−２，４−ジオンおよびそれらの治療用途 | |
| AU597187B2 (en) | 2-{ (4-piperidyl)methyl}benzofuro{2,3-c}pyridine derivatives, their preparation and their application in therapy | |
| US7470683B2 (en) | Tetracyclic compounds | |
| NO173542B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive aminotetrahydronaftalenderivater | |
| CN116478134A (zh) | Ssri/5-ht1a双靶点抗抑郁甲酰哌啶类化合物及其制备方法和应用 | |
| CS266586B2 (en) | Method of new racemic or optically active berbane derivatives production | |
| JP3926284B2 (ja) | 新規なインドリン化合物、その調製方法及びそれを含有する医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |